Basic science and clinical frontiers of sarcoma treatment by Tsuchiya Hiroyuki












Basic science and clinical frontiers of sarcoma treatment 
 
Hiroyuki Tsuchiya 
Department of Orthopaedic Surgery, Graduate School of Medical Science, Kanazawa 
University, 13-1 Takara-machi, Kanazawa 920-8641, Japan 
e-mail: tsuchi@med.kanazawa-u.ac.jp 
 
In 2008, 12.7 million cancer cases and 7.6 million cancer deaths are estimated to have 
occurred worldwide. Breast cancer is the most frequently diagnosed cancer and the 
leading cause of cancer death among females, accounting for 23% of the total cancer 
cases and 14% of the cancer deaths. Lung cancer is the leading cancer site in males, 
comprising 17% of the total new cancer cases and 23% of the total cancer deaths [1]. 
 In contrast, bone and soft tissue sarcomas are relatively rare, comprising fewer 
than 1% of all cancers. In turn, the incidence rate of bone sarcomas is approximately 
one tenth that of soft tissue sarcomas.  
 Whereas carcinomas are derived from epithelial cells, sarcomas are derived 
from mesodermal (middle layer) cells. Efforts to devise a useful and comprehensive 
histological classification for the various forms of sarcoma have proven difficult, in part 
because of their mesodermal origins. Complicating the classification efforts are the 
diagnostic difficulties that some sarcomas pose at the histological level, and the relative 
paucity of pathologists (2% in Japan) who specialize in bone and soft tissue tumors. 
 Over the past four decades, the treatment strategy for sarcomas of the 
extremities has significantly changed. Forty years ago, limb amputation surgery was 
the standard treatment for osteosarcoma, despite which the 5-year survival rate was 
only about 10%. After the introduction of multimodal therapies including chemotherapy, 
5-year survival rates have improved to over 60%, and limb preservation surgery has 
now become the standard surgical approach. Osteosarcoma thus no longer has a dismal 
prognosis, and indeed, in selected cases, marginal excisions of the tumor are now being 
performed to provide patients with even better limb function [2, 3]; multicenter studies 
have been indispensable to the basic science and clinical advancements that have been 
occurring.  
 Among the several staging systems that have been developed for sarcoma, the 
MSTS (Musculoskeletal Tumor Society) surgical staging system [4] has become the 
preferred one for sarcoma of the extremities. Compartment theory is a key concept 
behind current surgical approaches to sarcomas of the extremities: recognition that the 
various tissues in the extremities can be separated into multiple compartments which 
constitute anatomical barriers (i.e., periosteum, cartilage, and fascia) allows surgeons to 
perform wide curative excision without exposure of the malignant neoplasm.  
 It is also important for oncologists in other fields to understand the biological 
behavior and treatment strategies for malignant bone tumors. One consequence of 
advances in multimodal therapies against various cancers—and the resultant 
improvement in prognoses—is that the number of patients with metastatic bone tumors 
increases every year. Although medication and/or irradiation therapy can help control 
the pain caused by metastatic bone tumors, only surgical treatment can securely restore 
the biomechanical strength of the affected bone, which in turn can provide an important 
improvement in patient quality of life.  
 This issue of the International Journal of Clinical Oncology contains a series of 
review articles by Japanese authorities in the field of sarcoma that together should 
provide a comprehensive description of the current status of basic science research and 
clinical treatment approaches to sarcoma. I trust that these review articles will become 
bridges between sarcoma oncologists and oncologists in other fields. 
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